Myeloma Patients Europe

04/02/2026

Today is World Cancer Day. Let’s unite to raise awareness about the need for people-centred care. Every story matters, and together MPE and our members are working to make a difference across Europe!

https://f.mtr.cool/vsjusiliri

03/02/2026

Early intervention in high-risk smouldering myeloma: The GEM-CESAR trial explores whether early rescue treatment with daratumumab, pomalidomide and dexamethasone can benefit people with high-risk smouldering myeloma before it progresses.

Dr. Bruno Paiva discusses the main findings from this ASH 2025 presentation.

Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main results of the GEM-CESAR clinical trial presented at the American Society of Hematology (A...

02/02/2026

Acute kidney failure (known as myeloma kidney or cast nephropathy) is often an early symptom of myeloma. As well as causing back pain, it can also severely reduce the kidney’s functionality.

Learn more about diagnosis on our website. https://f.mtr.cool/qwvxfbhvdh

29/01/2026

We're delighted to welcome Prof. Dr. Jelena Bila to MPE's Medical Advisory Committee (MAC).

Prof. Bila is Professor of Internal Medicine and Hematology at the University of Belgrade, Serbia, and Head of the Department for Multiple Myeloma at the Hematology Clinic of the University Clinical Centre of Serbia.

MPE's MAC helps to provide evidence-based advice, expert opinions and support related to the treatment, diagnosis, care, and research of myeloma and AL amyloidosis, which we use throughout our work.

We look forward to working with Prof. Bila to continue advancing patient care in myeloma across Europe.

28/01/2026

Are you getting the most out of your appointments?

Keeping a simple diary can help you communicate what really matters. Note symptoms when they happen. Record questions as they come to mind. List medications or doses you're unsure about. Note good days too - patterns matter.

Try keeping a notebook, notes app, or calendar and at your next appointment, you'll have a clear picture to share to ensure a great conversation.

27/01/2026

The inMMyCAR study introduces KLN1010, a novel "in vivo" CAR T-cell therapy that targets BCMA without the need for cell collection and manufacturing.

Dr. Phoebe Joy Ho, speaking at shares promising early results showing very good responses with no serious cytokine release syndrome or neurotoxicity in the first patients treated.

Watch to understand this groundbreaking therapy

Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, explains the results of inMMyCAR, a late breaking abstract p...

26/01/2026

MPE's Access and Policy Manager, Monica Racovita and Co-CEO, Kate Morgan, have co-authored a new paper as part of the ASCERTAIN project – a Horizon Europe initiative addressing disparities in access to innovative health technologies across Europe.

The project aims to develop transparent pricing, cost-effectiveness and reimbursement approaches to improve affordability and timely patient access across Europe.

This includes the ACCESS2MEDS Toolbox for transparent decision-making. You can read the study now at https://www.sciencedirect.com/science/article/pii/S2211883726000054

26/01/2026

Minimal residual disease (MRD) testing is becoming an important tool for measuring how well myeloma treatment is working. It can detect tiny amounts of myeloma cells that standard tests might miss, helping your healthcare team make informed decisions about your treatment journey.

Want to learn more about MRD? https://f.mtr.cool/yvvsmptnwu

21/01/2026

How are those New Year's resolutions going? Don't be hard on yourself if you're finding it difficult!

Forget rigid resolutions. Living with myeloma or AL amyloidosis may mean adapting to how you feel each day. Try setting 'flexible intentions and healthy habits' instead - small, achievable wellness goals you can adjust depending on how you are feeling.

What can you do for yourself this week?

20/01/2026

Highlights from ASH2025

Dr. Charlotte Pawlyn explains the MajesTEC-3 trial. This showed unprecedented benefits when teclistamab combined with daratumumab is used earlier in the myeloma treatment pathway.

https://f.mtr.cool/xpuddktusu

Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explain the main results of Majestec...

19/01/2026

Smouldering myeloma (also called asymptomatic myeloma) is an early form of myeloma that usually progresses to active disease over time.

Because it typically causes no symptoms, it's often discovered by chance through blood tests showing elevated protein levels.

About 1 in 10 patients will develop active myeloma within the first year of diagnosis – so it's important to get regular blood tests!

Learn more: https://f.mtr.cool/motxccbewg

14/01/2026

New research published: what matters most to myeloma patients about treatment

We're proud to share groundbreaking research published in Frontiers in Hematology, led by MPE's research team with 901 myeloma patients across 22 European countries.

This research further evidences the need for individualised treatment planning that considers patient preferences, lifestyle and values.

We'll be releasing a short summary report soon.

Read the full open-access study: Frontiers | Myeloma patients’ attitudes and perceived burden of treatment administration routes and locations: insights from a pan-European survey. https://f.mtr.cool/bldmrevchx

hashtag hashtag hashtag hashtag hashtag

IntroductionUnderstanding patients’ experiences of treatment and their attitudes towards different options is critical to enabling patient-centered care. The...